LCH‐I: A randomized trial of etoposide vs. vinblastine in disseminated langerhans cell histiocytosis

Stephan Ladisch, Helmut Gadner, Maurizio Arico, Valerie Broadbent, Nicole Grois, Ake Jacobson, Diane Komp, H. Stacy Nicholson

Research output: Contribution to journalArticle

101 Scopus citations

Abstract

An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH‐I, which compares etoposide (VP‐16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide‐associated (therapy‐induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)107-110
Number of pages4
JournalMedical and Pediatric Oncology
Volume23
Issue number2
DOIs
StatePublished - 1994

    Fingerprint

Keywords

  • epipodophyllotoxin
  • monocyte‐macrophage system
  • secondary malignancies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Ladisch, S., Gadner, H., Arico, M., Broadbent, V., Grois, N., Jacobson, A., Komp, D., & Nicholson, H. S. (1994). LCH‐I: A randomized trial of etoposide vs. vinblastine in disseminated langerhans cell histiocytosis. Medical and Pediatric Oncology, 23(2), 107-110. https://doi.org/10.1002/mpo.2950230207